Vebreltinib before surgery for MET-altered lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether taking vebreltinib before surgery can help shrink lung cancer tumors with a specific genetic change (MET alteration). It may make surgery more effective for people with stage III non-small cell lung cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with non-small cell lung cancer (NSCLC) that is stage III or early stage IV.
- Your tumor has a specific genetic change called a MET alteration (either a MET exon 14 skipping mutation or MET amplification).
- You are healthy enough to have surgery, and your doctor thinks the tumor can be completely removed.
- You have not had prior treatment for lung cancer with targeted therapy, immunotherapy, or an investigational drug.
- You are not pregnant or breastfeeding, and you agree to use effective contraception if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a targeted drug called vebreltinib given before surgery to people with a specific type of non-small cell lung cancer that has a MET gene change. The goal is to see if it can shrink the tumor enough to make surgery more successful.
This trial tests a new targeted drug, vebreltinib, combined with standard chemotherapy as the first treatment for advanced non-small cell lung cancer that has a specific marker called MET overexpression. The goal is to see if this combination can help control the cancer better than chemotherapy alone.
This trial tests a targeted drug (Vebreltinib) combined with standard chemotherapy in people with a specific type of advanced non-squamous lung cancer that has a MET gene change (amplification or overexpression). The goal is to see if this combination works better than chemo alone.
This trial tests a combination of two targeted drugs (Vebreltinib and PLB1004) for people with advanced non-small cell lung cancer that has a specific EGFR mutation and has developed MET amplification or overexpression after previous EGFR-targeted therapy. The goal is to see if this combination can help shrink tumors or slow their growth.
This study tests a new targeted pill (vebreltinib) for people with advanced non-small cell lung cancer that has a specific gene change (MET exon 14 mutation). It is for people who have not had much or any prior treatment. The goal is to see if this medicine can shrink tumors and improve outcomes.
This trial tests a new targeted therapy (vebreltinib plus PLB1004) against standard chemotherapy for people with advanced non-small cell lung cancer that has a specific change (EGFR mutation) and MET protein, and has stopped responding to earlier EGFR treatment.
Hear when a new Potentially Resectable MET-altered Non-Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.